CA2211666A1 - Method for detecting nucleic acid sequence variations - Google Patents
Method for detecting nucleic acid sequence variationsInfo
- Publication number
- CA2211666A1 CA2211666A1 CA002211666A CA2211666A CA2211666A1 CA 2211666 A1 CA2211666 A1 CA 2211666A1 CA 002211666 A CA002211666 A CA 002211666A CA 2211666 A CA2211666 A CA 2211666A CA 2211666 A1 CA2211666 A1 CA 2211666A1
- Authority
- CA
- Canada
- Prior art keywords
- nucleic acid
- mismatch
- sequence
- dna
- solid support
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 46
- 150000007523 nucleic acids Chemical group 0.000 title claims abstract description 33
- 108091028043 Nucleic acid sequence Proteins 0.000 title claims abstract description 13
- 238000003776 cleavage reaction Methods 0.000 claims abstract description 23
- 230000007017 scission Effects 0.000 claims abstract description 23
- 239000007787 solid Substances 0.000 claims abstract description 20
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 18
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 18
- 238000006243 chemical reaction Methods 0.000 claims abstract description 10
- 238000005259 measurement Methods 0.000 claims abstract description 9
- 230000003287 optical effect Effects 0.000 claims abstract description 6
- 108020004414 DNA Proteins 0.000 claims description 21
- 108090000623 proteins and genes Proteins 0.000 claims description 21
- 239000012634 fragment Substances 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 238000012216 screening Methods 0.000 claims description 4
- 108010064144 endodeoxyribonuclease VII Proteins 0.000 claims description 3
- 230000003100 immobilizing effect Effects 0.000 claims description 2
- 239000013043 chemical agent Substances 0.000 claims 1
- 238000004020 luminiscence type Methods 0.000 claims 1
- 230000001235 sensitizing effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 description 14
- 230000035772 mutation Effects 0.000 description 11
- 239000013610 patient sample Substances 0.000 description 11
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 108060003196 globin Proteins 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- 108091092878 Microsatellite Proteins 0.000 description 1
- 108010010677 Phosphodiesterase I Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000012254 genetic linkage analysis Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical group OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
- C12Q1/683—Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
A method of analyzing nucleic acid-containing samples for sequence variations relative to standard nucleic acid sequences, which method comprises providing a single-stranded standard nucleic acid sequence immobilized on a solid support, hybridizing a nucleic acid strand derived from a sample to the immobilized strand, subjecting the nucleic acid complex formed to (i) mismatchinduced cleavage or (ii) mismatch-terminated extension reactions, and detecting possible cleavage or extension-termination by optical measurement on the solid support.
Description
W O 96/23903 PCTJSE9'~ 9 a~ FOR ~1~ lN~ ~nUCLEIC ACID ~L '~F V~iRIATIONS
The present invention relates to a method for detecting variations in the sequences of nucleic acid fragments, particularly in the DNA sequences of genes or gene fragments in patient samples in relation to the wild type genes.
Clinical analyses of DNA sequences are typically directed to det~rm;n;ng how a gene in a patient sample differs from a prototypical normal sequence. DNA sequencing through the chain t~rm;nAtion method developed by Sanger and Coulson (Sanger et al., Proc. Natl. Acad. Sci. USA
1977; 74: 5463-5467), and the chemical degradation method developed by Maxam and Gilbert (Maxam and Gilbert, Proc.
Natl. Acad. Sci. USA 1977; 74: 560-564), or using techniques such as Sequencing By Hybridization (SBH) or Sequencing By Synthesis (see e.g. WO 93/21340) all have the potential to identify mutations and in the same process also reveal the consequence of the mutation at the level of protein coding etc.
For screening purposes, however, it is often sufficient, at least initially, to identify deviations from the normal sequence but without directly revealing how a sequence differs from the normal one or only roughly locating the mutation. There are a number of such techniques which speed up analysis as compared to those that involve DNA sequence determ;nAtion.
Methods to scan or screen for mutations may be divided into two groups, i.e. those that identify mutations trough altered properties of heteroduplexes, i.e. base-paired molecules composed of one strand from the normal sequence and a complementary strand derived from the patient sample, and those that observe properties of single stranded molecules or of homoduplexes. Examples from the ~irst category of methods are RNAse cleavage of mismatched positions in hybrids between an RNA strand and a complementary DNA strand ~Myers R. M. et al., Science 1985;
230:1242-1246). It is also possible to detect mismatches in CA 022ll666 l997-07-29 heteroduplexes via their effect upon the melting behaviour of the molecules as they migrate in a gel under increasingly denaturing conditions (Myers R. M. et al., Nature 1985; 313: 495-498). One of the more popular methods uses base-modifying chemistry to selectively sensitize mismatched bases for subsequent cleavage (Cotton R. G. H.
et al., Proc. Natl. Acad. Sci. USA 1988; 85: 4397-4401; and Montadon A. J. et al., Nucl. Acids. Res. 1989i 1 (9): 3347-3358). There is also a method where mismatched bases are modified so that the modified positions in a replication template will terminate a subsequent primer-extension reaction (Ganguly A., Prockop D. J., Nucl. Acids Res. 1990;
;L~ (13): 3933-3939). Recently, enzyme systems serving the purpose to detect mismatched bases in DNA duplexes have been applied for this purpose (Lu A-L, Hsu I-C, Genomics 1992; ;L~L: 249-255; and Yeh Y-C et al., J. Biol. Chem. 1991;
266: 6480-6484). Such enzyme systems may cleave most or all mismatched positions in DNA strands with a length of at least several hundred bases. An exemplary suc~ enzyme system is T4 endonuclease VII (Youil R. et al, Proc. Natl.
Acad. Sci. USA 1995; 92: 87-91).
Typically, in the methods where sequence differences are demonstrated through the cleavage or modification of mismatched positions in heteroduplexes, the results are evaluated by gel electrophoretic separation of the strands, providing an estimate of the position of the mismatch.
Recently, automated sequencers e~uipped for fluorescent detection of the molecules have been used for this purpose (Verpy E. et al., Proc. Natl. Acad. Sci. USA 1994; 91:
1873-1877). The necessary electrophoretic separation is, however, laborious and time-consuming.
WO 93/20233 discloses a method for identifying a base pair mismatch at a site in a nucleic acid by labelling a single stranded target nucleic acid sequence at two sites on either side of the target site, fixing the doubly labelled nucleic acid to a solid support at one end, hybridizing a corresponding wild type nucleic acid fragment to the target sequence, exposing the nucleic acid hybrid to WO 96J23903 PCT~SE~>C~000~5 a mismatch-cleaving enzyme, and after a wash detecting the presence of both labels or one label, that on the end fixed to the solid support or that washed away. This method avoids electrophoretic separation, but is disadvantagous in that it inter alia does not permit use for the simultaneous screening of a plurality of different target sequences on a single solid support.
The object of the present invention is to provide an improved method for identifying sequence discrepancies between nucleic acid sequences, such as normal and patient sample genes or gene fragments, by mismatch-techniques, like those listed above, but which does not use any gel electrophoretic sepaxation, and which may readily be adapted to array formats for multiple screening purposes.
According to the invention, this object is achieved by providing a single-stranded prototypical normal nucleic acid sequence, or stAn~rd (wild type) sequence, immobilized on a solid support, hybridizing a nucleic acid strand derived from a patient sample to the immobilized strand, subjecting the nucleic acid hybridization complex formed to (i) mismatch-induced cleavage or (ii) mismatch-restricted extension reactions, and detecting possible cleavage or extension-t~rm;n~tion by optical measurement on the solid support.
The nucleic acid sequences are preferably DNA
sequences, such as genomic DNA sequences.
In a preferred embodiment, sets of the same or different normal nucleic acid strands, especially DNA, are immobilized in a linear or, preferably, 2-~;mencional planar array to permit either several patient derived samples to be tested in parallel, or, more preferably, several nucleic acid sequences, especially gene fragments, derived from one individual to be tested at the same time.
When carrying out such an embodiment of the invention by mismatch-induced cleavage of DNA hybrids, either the free ends of the patient DNA strands and/or the normal strands may be labelled, e.g. with a dye, such as with a fluorophore or a chromophore. After washes, the number of W 096/23903 PCT/SE~C;~A_95 DNA strands bound to their respective positions may be estimated by measuring the local label signal, e.g.
fluorescence. Then, cleavage of DNA heteroduplexes at mutation positions is performed using any of the above-mentioned techniques, followed by washes, to remove singlestrands or base-paired DNA segments, depending on whether the molecules have been cleaved in one or both strands. In general, it is thus desirable to attach the molecules to the support so that the strands that bear detectable functions are not removed under denaturing conditions, unless they have been cleaved. Examples of linkages of the DNA to the support that are suitable include binding by a biotin-avidin/streptavidin interaction or covalent bonds, e.g. formed by chemically coupling DNA to the support or by ligating the DNA strand to an oligonucleotide, stably bound to the support. Techniques suitable for such attachment are known to those skilled in the art. After cleavage and denaturing washes, another measurement of the local fluorescence in each position is performed, and the ratio of fluorescence after versus before cleavage is estimated.
Any significant reduction of the fluorescence as compared to that before cleavage indicates mismatches in at least some of the strands from the patient samples.
An analogous procedure may be used in the case of mismatch-restricted extension, where extension products may be labelled by incorporating detectable functions as modified nucleotides during the extension reaction.
Measurement of cleavage or extension termination may also be performed by optical "label-free" techni~ues, such as, for example, mass or refractive index sensing techniques based on evanescent wave sensing, such as surface plasmon resonance (SPR) based methods.
Differences in the tendency to non-specific cleavage as a function of factors such as hybrid length, base composition or curvature may be weighted in as a background against which to compare the results of the analysis. The above method permits a very large number of templates to be simultaneously analyzed in the described manner, and also WO 96/23903 PCr/SE9CJO~9S
relatively small contributions of mutant sequences may give rise to a detectably different signal.
Complications of the analysis due to the presence of polymorphisms, i.e. normal variations in a sequence under 5 study, may be overcome by investigating several independent sequence variants.
There are a number of techniques known in the art for immobilizing the desired templates to the solid support.
For example, short oligonucleotides arrayed on a two-~;m~n~ional support may be used to ligate one strand from aspecific PCR product by using primers that provide a 5' single stranded extension, as described by Newton C. R., Nucl. Acids Res. 1993; 21: 1155-1162. This technique would permit the assortment of large sets of different PCR
products to the appropriate positions in the array by hybridization to the corresponding immobilized oligonucleotides via a splint.
The arrays themselves supporting oligonucleotides or longer nucleic acid strands, such as DNA strands, in defined positions and to which the templates may be immobilized may be prepared by any of a number of techni~ues known in the art. One such techni~ue, which is described in the International patent application No.
PCT/SE95/01~20, involves the bundling of structures cont~;n;ng DNA strands, followed by sectioning and deposition on a planar surface. Alternatively, the oligonucleotides may be bound to the solid support via a specific binding pair, such as biotin and avidin or streptavidin. For example, the primers can be provided with biotin handles in connection with their preparation, and then the biotin-labelled oligonucleotides can be attached to a streptavidin-coated support. The oligonucleotides can also be bound by a linker arm, such as a covalently bonded hydrocarbon chain, e.g. a C10-2o chain. As another alternative, the oligonucleotides can be bound directly to the solid support, such as by epoxide/amine coupling chemistry.
CA 022ll666 l997-07-29 The solid support can be a plate or chip of glass, silicon or other material. The solid support can also be coated, such as with gold or silver. Coating may facilitate attachment of the oligonucleotides to the solid support.
Measurement of the fluorescence from fluorophore-labelled duplexes may be performed by methods known in the art, such as by a two-~;m~n-sional diode array or a CCD
(charge-coupled device) camera, ~or example.
The patient samples may be simply labelled by 10 selecting a 5' fluorophore-labelled primer in the amplification reaction used for amplifying the DNA strand or strands of interest. It is also possible to label the st~n~rd sequence on the solid support in the 3' position by tailing with terminating fluorophore-labelled 15 nucleotides (Prober J. M. et al., Science 1987; 238: 336-341), and using the enzyme terminal deoxynucleotidyl transferase (Maniatis T. et al., Molecular cloning: A
laboratory manual. New York: Cold Spring Harbor Press, 1982).
The hybridization of patient strands to the arrayed templates is simplified if these are first rendered single-stranded, e.g. by digestion with lambda exonuclease (Higuchi R. G. et al., Nucl. Acids Res. 1989; 17(14): 1989, and Nikiforov T . T . et al., PCR Meth. Applic. 1994; 3: 285-25 291). In this regard the fluorophore label, which is present at the 5' end of the amplified strands, conveniently protects this strand against degradation.
Among advantages of the method of the invention may be mentioned the circumstance that a normal sequence may be selected as a st~n~rd against which to compare the patient sample, which means that both homozygous and heterozygous mutations may be monitored. The technique may have obvious advantages for sc~nn; ng for clinically important mutations, ultimately in all estimated human 65,000 genes. However, the technique could also be useful as a forensic tool, rapidly identifying differences between DNA samples or for the typing of genes such as transplantation genes. In genetic linkage analysis, the method of the invention would W O 96/23903 P~/SE9~ 5S
provide access to a much larger set of genetic markers than RPLFs or microsatellites, since any point mutation occurring in segments of DNA could be scored. In p-articular, the method of the invention would be highly useful to identify the location of homozygous genomic regions in individuals affected by recessive disorders by being homozygous by decent, i.e. having inherited the sam.e mutated gene through parental lineages.
The invention will be illustrated further by the following non-limiting example.
EXAMPLE
A PCR product from an individual having the normal form of the amplified globin gene is generated in a reaction where one o~ the primers has a 5' extension-sequence, interrupted by non-nucleotide residues, such as for instance hexaethylene glycol residues (HEG) (other oligonucleotide sequence modifications serving a similar purpose have been described by Newton et al., Nucl. Acids Res. 1993; ~1:1155-1162). After PCR, the 5' extension will remain single stranded and is used to hybridize and ligate the PCR product to a solid support which has previously been modified by the coupling of a suitable oligonucleotide with a free 3'end, and to which a complementary oligonucleotide has been hybridized such that this hybridized oligonucleotide can also hybridize to the 5l extension of the PCR product, and permit the PCR product to be ligated to the oligonucleotide on the support. After denaturing washes, the free 3' end of the amplified strand r~m~;n;ng on the support is modified with a dideoxynucleotide with an added fluorophore, using the enzyme t~rm;nAl deoxynucleotide transferase. A
corresponding PCR product is derived from a patient in order to investigate if the globin gene in this patient differs from the normal sequence. In this amplification reaction, a 5' phosphorylated primer lacking any non-nucleotidic sequences is used instead of the HEG-modified primer used for the amplification of the normal gene.
Instead the opposite primer is modified through the W O 96/23903 PCT/SE~G/C~J~S
addition of a biotin 5' reside which will protect this strand from digestion by the 5' exonuclease ~-exonuclease (another 5' modification, serving a similar purpose has been described by Nikiforov et al., PCR Meth. Appl. 1994;
~:285-291). An excess of the single strands from the amplified patient sample is then hybridized to the single strands bound to the support. After the fluorescence from the immobilized molecules has been recorded, the duplex molecules are exposed to reagents that cleave mismatched positions in duplex DNA, such as T4 endonuclease VII, as taught by Youil et al., Proc. Natl. Acad. Sci. USA 1995;
~2: 87-91. After denaturing washes, another fluorescence reading is then taken to determine if the support-bound strands have undergone cleavage, indicative of a mismatch in the hybrid with the strand derived from the patient. Any such reduction then indicates a sequence variation in the globin gene sequence of the patient and may prompt further analysis of the gene in this patient, e.g. by DNA sequence analysis.
The above described example of carrying out the invention may be modified in two ways to increase the probability and speed of detecting any mutations. The supports may be designed so that not only the 5' end of the st~n~rd sequence but also the 3' end of the patient sample are stably attached to the support, e.g. through ligation, and, along with the 3' end of the st~n~rd sequence, also the 5' end of the patient sample may be modified with a fluorophore, for instance by attaching a fluorophore instead of the biotin group in the example above. In this manner, cleavage of either or both strands of the immobilized heteroduplex may be detected, increasing the probability of detecting mutations. The other suggested modification of the above protocol is by performing the analysis for a large num.ber of samples in parallel. Thus, at defined locations on a 2-~-m~n~ional array the corresponding genes or gene fragments from many patients may be hybridized. Alternatively, and more importantly, many different gene sequences in one individual may be WO 96123903 PCTJSE~GJ00-95 co,mpared to standard variants of the corresponding sequences, immobilized in discrete locations.
The invention is, of course, not restricted to the embodiments specifically described above, but many changes and modifications may be made within the scope of the general inventive concept as defined in the following claims.
The present invention relates to a method for detecting variations in the sequences of nucleic acid fragments, particularly in the DNA sequences of genes or gene fragments in patient samples in relation to the wild type genes.
Clinical analyses of DNA sequences are typically directed to det~rm;n;ng how a gene in a patient sample differs from a prototypical normal sequence. DNA sequencing through the chain t~rm;nAtion method developed by Sanger and Coulson (Sanger et al., Proc. Natl. Acad. Sci. USA
1977; 74: 5463-5467), and the chemical degradation method developed by Maxam and Gilbert (Maxam and Gilbert, Proc.
Natl. Acad. Sci. USA 1977; 74: 560-564), or using techniques such as Sequencing By Hybridization (SBH) or Sequencing By Synthesis (see e.g. WO 93/21340) all have the potential to identify mutations and in the same process also reveal the consequence of the mutation at the level of protein coding etc.
For screening purposes, however, it is often sufficient, at least initially, to identify deviations from the normal sequence but without directly revealing how a sequence differs from the normal one or only roughly locating the mutation. There are a number of such techniques which speed up analysis as compared to those that involve DNA sequence determ;nAtion.
Methods to scan or screen for mutations may be divided into two groups, i.e. those that identify mutations trough altered properties of heteroduplexes, i.e. base-paired molecules composed of one strand from the normal sequence and a complementary strand derived from the patient sample, and those that observe properties of single stranded molecules or of homoduplexes. Examples from the ~irst category of methods are RNAse cleavage of mismatched positions in hybrids between an RNA strand and a complementary DNA strand ~Myers R. M. et al., Science 1985;
230:1242-1246). It is also possible to detect mismatches in CA 022ll666 l997-07-29 heteroduplexes via their effect upon the melting behaviour of the molecules as they migrate in a gel under increasingly denaturing conditions (Myers R. M. et al., Nature 1985; 313: 495-498). One of the more popular methods uses base-modifying chemistry to selectively sensitize mismatched bases for subsequent cleavage (Cotton R. G. H.
et al., Proc. Natl. Acad. Sci. USA 1988; 85: 4397-4401; and Montadon A. J. et al., Nucl. Acids. Res. 1989i 1 (9): 3347-3358). There is also a method where mismatched bases are modified so that the modified positions in a replication template will terminate a subsequent primer-extension reaction (Ganguly A., Prockop D. J., Nucl. Acids Res. 1990;
;L~ (13): 3933-3939). Recently, enzyme systems serving the purpose to detect mismatched bases in DNA duplexes have been applied for this purpose (Lu A-L, Hsu I-C, Genomics 1992; ;L~L: 249-255; and Yeh Y-C et al., J. Biol. Chem. 1991;
266: 6480-6484). Such enzyme systems may cleave most or all mismatched positions in DNA strands with a length of at least several hundred bases. An exemplary suc~ enzyme system is T4 endonuclease VII (Youil R. et al, Proc. Natl.
Acad. Sci. USA 1995; 92: 87-91).
Typically, in the methods where sequence differences are demonstrated through the cleavage or modification of mismatched positions in heteroduplexes, the results are evaluated by gel electrophoretic separation of the strands, providing an estimate of the position of the mismatch.
Recently, automated sequencers e~uipped for fluorescent detection of the molecules have been used for this purpose (Verpy E. et al., Proc. Natl. Acad. Sci. USA 1994; 91:
1873-1877). The necessary electrophoretic separation is, however, laborious and time-consuming.
WO 93/20233 discloses a method for identifying a base pair mismatch at a site in a nucleic acid by labelling a single stranded target nucleic acid sequence at two sites on either side of the target site, fixing the doubly labelled nucleic acid to a solid support at one end, hybridizing a corresponding wild type nucleic acid fragment to the target sequence, exposing the nucleic acid hybrid to WO 96J23903 PCT~SE~>C~000~5 a mismatch-cleaving enzyme, and after a wash detecting the presence of both labels or one label, that on the end fixed to the solid support or that washed away. This method avoids electrophoretic separation, but is disadvantagous in that it inter alia does not permit use for the simultaneous screening of a plurality of different target sequences on a single solid support.
The object of the present invention is to provide an improved method for identifying sequence discrepancies between nucleic acid sequences, such as normal and patient sample genes or gene fragments, by mismatch-techniques, like those listed above, but which does not use any gel electrophoretic sepaxation, and which may readily be adapted to array formats for multiple screening purposes.
According to the invention, this object is achieved by providing a single-stranded prototypical normal nucleic acid sequence, or stAn~rd (wild type) sequence, immobilized on a solid support, hybridizing a nucleic acid strand derived from a patient sample to the immobilized strand, subjecting the nucleic acid hybridization complex formed to (i) mismatch-induced cleavage or (ii) mismatch-restricted extension reactions, and detecting possible cleavage or extension-t~rm;n~tion by optical measurement on the solid support.
The nucleic acid sequences are preferably DNA
sequences, such as genomic DNA sequences.
In a preferred embodiment, sets of the same or different normal nucleic acid strands, especially DNA, are immobilized in a linear or, preferably, 2-~;mencional planar array to permit either several patient derived samples to be tested in parallel, or, more preferably, several nucleic acid sequences, especially gene fragments, derived from one individual to be tested at the same time.
When carrying out such an embodiment of the invention by mismatch-induced cleavage of DNA hybrids, either the free ends of the patient DNA strands and/or the normal strands may be labelled, e.g. with a dye, such as with a fluorophore or a chromophore. After washes, the number of W 096/23903 PCT/SE~C;~A_95 DNA strands bound to their respective positions may be estimated by measuring the local label signal, e.g.
fluorescence. Then, cleavage of DNA heteroduplexes at mutation positions is performed using any of the above-mentioned techniques, followed by washes, to remove singlestrands or base-paired DNA segments, depending on whether the molecules have been cleaved in one or both strands. In general, it is thus desirable to attach the molecules to the support so that the strands that bear detectable functions are not removed under denaturing conditions, unless they have been cleaved. Examples of linkages of the DNA to the support that are suitable include binding by a biotin-avidin/streptavidin interaction or covalent bonds, e.g. formed by chemically coupling DNA to the support or by ligating the DNA strand to an oligonucleotide, stably bound to the support. Techniques suitable for such attachment are known to those skilled in the art. After cleavage and denaturing washes, another measurement of the local fluorescence in each position is performed, and the ratio of fluorescence after versus before cleavage is estimated.
Any significant reduction of the fluorescence as compared to that before cleavage indicates mismatches in at least some of the strands from the patient samples.
An analogous procedure may be used in the case of mismatch-restricted extension, where extension products may be labelled by incorporating detectable functions as modified nucleotides during the extension reaction.
Measurement of cleavage or extension termination may also be performed by optical "label-free" techni~ues, such as, for example, mass or refractive index sensing techniques based on evanescent wave sensing, such as surface plasmon resonance (SPR) based methods.
Differences in the tendency to non-specific cleavage as a function of factors such as hybrid length, base composition or curvature may be weighted in as a background against which to compare the results of the analysis. The above method permits a very large number of templates to be simultaneously analyzed in the described manner, and also WO 96/23903 PCr/SE9CJO~9S
relatively small contributions of mutant sequences may give rise to a detectably different signal.
Complications of the analysis due to the presence of polymorphisms, i.e. normal variations in a sequence under 5 study, may be overcome by investigating several independent sequence variants.
There are a number of techniques known in the art for immobilizing the desired templates to the solid support.
For example, short oligonucleotides arrayed on a two-~;m~n~ional support may be used to ligate one strand from aspecific PCR product by using primers that provide a 5' single stranded extension, as described by Newton C. R., Nucl. Acids Res. 1993; 21: 1155-1162. This technique would permit the assortment of large sets of different PCR
products to the appropriate positions in the array by hybridization to the corresponding immobilized oligonucleotides via a splint.
The arrays themselves supporting oligonucleotides or longer nucleic acid strands, such as DNA strands, in defined positions and to which the templates may be immobilized may be prepared by any of a number of techni~ues known in the art. One such techni~ue, which is described in the International patent application No.
PCT/SE95/01~20, involves the bundling of structures cont~;n;ng DNA strands, followed by sectioning and deposition on a planar surface. Alternatively, the oligonucleotides may be bound to the solid support via a specific binding pair, such as biotin and avidin or streptavidin. For example, the primers can be provided with biotin handles in connection with their preparation, and then the biotin-labelled oligonucleotides can be attached to a streptavidin-coated support. The oligonucleotides can also be bound by a linker arm, such as a covalently bonded hydrocarbon chain, e.g. a C10-2o chain. As another alternative, the oligonucleotides can be bound directly to the solid support, such as by epoxide/amine coupling chemistry.
CA 022ll666 l997-07-29 The solid support can be a plate or chip of glass, silicon or other material. The solid support can also be coated, such as with gold or silver. Coating may facilitate attachment of the oligonucleotides to the solid support.
Measurement of the fluorescence from fluorophore-labelled duplexes may be performed by methods known in the art, such as by a two-~;m~n-sional diode array or a CCD
(charge-coupled device) camera, ~or example.
The patient samples may be simply labelled by 10 selecting a 5' fluorophore-labelled primer in the amplification reaction used for amplifying the DNA strand or strands of interest. It is also possible to label the st~n~rd sequence on the solid support in the 3' position by tailing with terminating fluorophore-labelled 15 nucleotides (Prober J. M. et al., Science 1987; 238: 336-341), and using the enzyme terminal deoxynucleotidyl transferase (Maniatis T. et al., Molecular cloning: A
laboratory manual. New York: Cold Spring Harbor Press, 1982).
The hybridization of patient strands to the arrayed templates is simplified if these are first rendered single-stranded, e.g. by digestion with lambda exonuclease (Higuchi R. G. et al., Nucl. Acids Res. 1989; 17(14): 1989, and Nikiforov T . T . et al., PCR Meth. Applic. 1994; 3: 285-25 291). In this regard the fluorophore label, which is present at the 5' end of the amplified strands, conveniently protects this strand against degradation.
Among advantages of the method of the invention may be mentioned the circumstance that a normal sequence may be selected as a st~n~rd against which to compare the patient sample, which means that both homozygous and heterozygous mutations may be monitored. The technique may have obvious advantages for sc~nn; ng for clinically important mutations, ultimately in all estimated human 65,000 genes. However, the technique could also be useful as a forensic tool, rapidly identifying differences between DNA samples or for the typing of genes such as transplantation genes. In genetic linkage analysis, the method of the invention would W O 96/23903 P~/SE9~ 5S
provide access to a much larger set of genetic markers than RPLFs or microsatellites, since any point mutation occurring in segments of DNA could be scored. In p-articular, the method of the invention would be highly useful to identify the location of homozygous genomic regions in individuals affected by recessive disorders by being homozygous by decent, i.e. having inherited the sam.e mutated gene through parental lineages.
The invention will be illustrated further by the following non-limiting example.
EXAMPLE
A PCR product from an individual having the normal form of the amplified globin gene is generated in a reaction where one o~ the primers has a 5' extension-sequence, interrupted by non-nucleotide residues, such as for instance hexaethylene glycol residues (HEG) (other oligonucleotide sequence modifications serving a similar purpose have been described by Newton et al., Nucl. Acids Res. 1993; ~1:1155-1162). After PCR, the 5' extension will remain single stranded and is used to hybridize and ligate the PCR product to a solid support which has previously been modified by the coupling of a suitable oligonucleotide with a free 3'end, and to which a complementary oligonucleotide has been hybridized such that this hybridized oligonucleotide can also hybridize to the 5l extension of the PCR product, and permit the PCR product to be ligated to the oligonucleotide on the support. After denaturing washes, the free 3' end of the amplified strand r~m~;n;ng on the support is modified with a dideoxynucleotide with an added fluorophore, using the enzyme t~rm;nAl deoxynucleotide transferase. A
corresponding PCR product is derived from a patient in order to investigate if the globin gene in this patient differs from the normal sequence. In this amplification reaction, a 5' phosphorylated primer lacking any non-nucleotidic sequences is used instead of the HEG-modified primer used for the amplification of the normal gene.
Instead the opposite primer is modified through the W O 96/23903 PCT/SE~G/C~J~S
addition of a biotin 5' reside which will protect this strand from digestion by the 5' exonuclease ~-exonuclease (another 5' modification, serving a similar purpose has been described by Nikiforov et al., PCR Meth. Appl. 1994;
~:285-291). An excess of the single strands from the amplified patient sample is then hybridized to the single strands bound to the support. After the fluorescence from the immobilized molecules has been recorded, the duplex molecules are exposed to reagents that cleave mismatched positions in duplex DNA, such as T4 endonuclease VII, as taught by Youil et al., Proc. Natl. Acad. Sci. USA 1995;
~2: 87-91. After denaturing washes, another fluorescence reading is then taken to determine if the support-bound strands have undergone cleavage, indicative of a mismatch in the hybrid with the strand derived from the patient. Any such reduction then indicates a sequence variation in the globin gene sequence of the patient and may prompt further analysis of the gene in this patient, e.g. by DNA sequence analysis.
The above described example of carrying out the invention may be modified in two ways to increase the probability and speed of detecting any mutations. The supports may be designed so that not only the 5' end of the st~n~rd sequence but also the 3' end of the patient sample are stably attached to the support, e.g. through ligation, and, along with the 3' end of the st~n~rd sequence, also the 5' end of the patient sample may be modified with a fluorophore, for instance by attaching a fluorophore instead of the biotin group in the example above. In this manner, cleavage of either or both strands of the immobilized heteroduplex may be detected, increasing the probability of detecting mutations. The other suggested modification of the above protocol is by performing the analysis for a large num.ber of samples in parallel. Thus, at defined locations on a 2-~-m~n~ional array the corresponding genes or gene fragments from many patients may be hybridized. Alternatively, and more importantly, many different gene sequences in one individual may be WO 96123903 PCTJSE~GJ00-95 co,mpared to standard variants of the corresponding sequences, immobilized in discrete locations.
The invention is, of course, not restricted to the embodiments specifically described above, but many changes and modifications may be made within the scope of the general inventive concept as defined in the following claims.
Claims (12)
1. A method of analyzing nucleic acid-containing samples for sequence variations relative to standard nucleic acid sequences, which method comprises providing a single-stranded standard nucleic acid sequence immobilized on a solid support, hybridizing a nucleic acid strand derived from a sample to the immobilized strand, subjecting the nucleic acid complex formed to (i) mismatch-induced cleavage or (ii) mismatch-terminated extension reactions, and detecting possible cleavage or extension-termination by optical measurement on the solid support.
2. The method according to claim 1, wherein said nucleic acid is DNA.
3. The method according to claim 1 or 2, wherein said standard sequence is a prototypical human gene sequence or a part thereof.
4. The method according to claim 1, 2 or 3, wherein said mismatch-induced cleavage comprises sensitizing mismatched bases by base-modifying chemical agents and subsequently cleaving the nucleic acid complex at the mismatch site by chemical means.
5. The method according to any one of claims 1 to 4, wherein said mismatch-induced cleavage comprises cleaving the nucleic acid complex at the mismatch site by means of an enzyme system, such as, for example, T4 endonuclease VII.
6. The method according to any one of claims 1 to 5, wherein fluorescence from a fluorophore label or luminescence from a luminescer label is measured.
7. The method according to any one of claims 4 to 6, wherein the free ends of nucleic acid strands derived from the sample are labelled.
8. The method according to any one of claims 4 to 7, wherein the free ends of the immobilized standard nucleic acid strands are labelled.
9. The method according to any one of claims 1 to 8, wherein said optical measurements are performed prior to and after said cleavage or chain extension reactions and the measurement results are compared with each other.
10. The method according to any one of claims 1 to 9, wherein sets of different standard nucleic acid sequences are immobilized at defined positions on the solid support and that a number of different nucleic acid fragments thereof derived from one individual are analyzed simultaneously.
11. The method according to claim 10, wherein said sets of standard nucleic acid sequences are provided in a two-dimensional array.
12. The method according to any one of claims 1 to 11 for screening of gene fragments for DNA sequence variations with respect to the corresponding wild type DNA sequences, which method comprises immobilizing a set of wild type DNA
strands in an array on a solid support, hybridizing different gene fragments derived from one individual to said immobilized wild type strands, subjecting the DNA
hybrids formed to (i) mismatch-induced cleavage or (ii) mismatch-terminated extension reactions, and detecting by optical measurement on the solid support cleavage or extension-termination of one or more of the DNA hybrids as indicative of mismatch between the gene fragment and the corresponding wild type sequence.
strands in an array on a solid support, hybridizing different gene fragments derived from one individual to said immobilized wild type strands, subjecting the DNA
hybrids formed to (i) mismatch-induced cleavage or (ii) mismatch-terminated extension reactions, and detecting by optical measurement on the solid support cleavage or extension-termination of one or more of the DNA hybrids as indicative of mismatch between the gene fragment and the corresponding wild type sequence.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9500341A SE9500341D0 (en) | 1995-01-30 | 1995-01-30 | Method for detecting DNA sequence variations |
| SE9500341-4 | 1995-01-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2211666A1 true CA2211666A1 (en) | 1996-08-08 |
Family
ID=20397030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002211666A Abandoned CA2211666A1 (en) | 1995-01-30 | 1996-01-30 | Method for detecting nucleic acid sequence variations |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0871766A1 (en) |
| JP (1) | JPH10513055A (en) |
| CA (1) | CA2211666A1 (en) |
| SE (1) | SE9500341D0 (en) |
| WO (1) | WO1996023903A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5770370A (en) * | 1996-06-14 | 1998-06-23 | David Sarnoff Research Center, Inc. | Nuclease protection assays |
| EP0843019A3 (en) * | 1996-11-08 | 2002-10-09 | Kyowa Medex Co., Ltd. | Method for determination of specific nucleic acid sequence, and a reagent therefor |
| AU6293798A (en) * | 1997-01-29 | 1998-08-18 | Institut Pasteur | Polynucleotide associated with the bo or bor syndrome, its corresponding polypeptide and diagnostic and therapeutic applications |
| DE1051515T1 (en) | 1998-01-27 | 2001-04-19 | Cytocell Ltd., Banbury | MODIFIED NUCLEIC ACID PROBES AND THEIR USE |
| DE19911130A1 (en) | 1999-03-12 | 2000-09-21 | Hager Joerg | Methods for identifying chromosomal regions and genes |
| US7166432B2 (en) | 1999-03-12 | 2007-01-23 | Integragen | Compositions and methods for genetic analysis |
| US20030039964A1 (en) * | 2000-05-09 | 2003-02-27 | Giffard Philip Morrison | Method |
| AU2003210259A1 (en) * | 2002-02-21 | 2003-09-09 | Nanogen Recognomics Gmbh | Method for detecting single nucleotide polymorphisms |
| AU2003289018A1 (en) * | 2002-12-10 | 2004-07-29 | Olympus Corporation | Method of analyzing nucleic acid mutation and method of analyzing gene expression |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3919293A (en) * | 1992-03-27 | 1993-11-08 | University Of Maryland At Baltimore | Detection of gene mutations with mismatch repair enzymes |
| US5750335A (en) * | 1992-04-24 | 1998-05-12 | Massachusetts Institute Of Technology | Screening for genetic variation |
-
1995
- 1995-01-30 SE SE9500341A patent/SE9500341D0/en unknown
-
1996
- 1996-01-30 CA CA002211666A patent/CA2211666A1/en not_active Abandoned
- 1996-01-30 EP EP96902038A patent/EP0871766A1/en not_active Withdrawn
- 1996-01-30 WO PCT/SE1996/000095 patent/WO1996023903A1/en not_active Application Discontinuation
- 1996-01-30 JP JP8523465A patent/JPH10513055A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO1996023903A1 (en) | 1996-08-08 |
| JPH10513055A (en) | 1998-12-15 |
| EP0871766A1 (en) | 1998-10-21 |
| SE9500341D0 (en) | 1995-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0754240B1 (en) | Ligase/polymerase-mediated genetic bit analysis of single nucleotide polymorphisms and its use in genetic analysis | |
| EP0929693B1 (en) | Multiplex polynucleotide capture methods and compositions | |
| US6232067B1 (en) | Adapter directed expression analysis | |
| JP4422897B2 (en) | Primer extension method for detecting nucleic acids | |
| JP3937136B2 (en) | Nucleotide polymorphism detection method | |
| US6248521B1 (en) | Amplification and other enzymatic reactions performed on nucleic acid arrays | |
| US6207381B1 (en) | Method for nucleic acid analysis | |
| EP1256632A2 (en) | High throughput polymorphism screening | |
| HUE025175T2 (en) | Method of dna sequencing by hybridisation | |
| Elenis et al. | A nanoparticle-based sensor for visual detection of multiple mutations | |
| US7611871B2 (en) | Method for the specific determination of DNA sequences by means of parallel amplification | |
| CA2211666A1 (en) | Method for detecting nucleic acid sequence variations | |
| AU2010331393B2 (en) | Method for designing probe in DNA microarray, and DNA microarray provided with probe designed thereby | |
| CA2298017A1 (en) | Multiple functionalities within an array element and uses thereof | |
| JP2003510054A (en) | A three-dimensional microarray system for parallel genotyping of single nucleotide polymorphisms | |
| JP4122317B2 (en) | Genetic testing method | |
| CN101065483B (en) | Identification method of base polymorphism | |
| Li et al. | Single nucleotide polymorphism analysis based on minisequencing coupled with a fluorescence microsphere technology | |
| KR20060131972A (en) | DNA array and mononucleotide polymorphism detection method | |
| JP2003135098A (en) | Genetic testing method | |
| WO2004046372A2 (en) | Improved genotyping | |
| JP2002209584A (en) | Method for detecting nucleotide polymorphism | |
| FR2920159A1 (en) | Identifying, analyzing and/or quantifying alleles of polymorphisms in nucleic acid sample, comprises amplifying double strand of nucleic acid sequence, eliminating heteroduplexes, hybridizing products, and determining and comparing signal | |
| HK1165508A (en) | A method for detecting nucleotide sequence of disease-associated nucleic acid molecule in samples under testing | |
| WO2004044242A1 (en) | Polymorphism assay |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |